-
-
-
-
-
-
-
Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the U.S. w
-
-
-
-
-
-
-
OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2018
-
1,217,305 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

